That said, it's not a good idea to rely on six months' worth of data to decide which stocks to buy. These two biotechs will likely reverse positions over the long run, with CRISPR performing much better than Ocugen. Read on to find out why the former is worth investing in while the latter should be avoided. Now, it's too early to look at CRISPR Therapeutics' financial results. Casgevy hasn't been on the market very long, not to mention that administering this therapy takes a while. The biotech's revenue in ...

The company's stock has dropped by 11.68% in the past month, falling short of the Medical sector's loss of 1.82% and the S&P 500's gain of 4.44%. For the full year, the Zacks Consensus Estimates project earnings of -$5.51 per share and a revenue of $89.43 million, demonstrating changes of -184.02% and -75.91%, respectively, from the preceding year. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a pro ...

But the silver lining of that process is you have time to accumulate a position. And, by not going all in, there's time to evaluate your thesis for owning the stock as time goes by. Here are three biotech stocks to buy while they're still in their early stages of growth. Recently, CRISP received Food and Drug Administration (FDA) approval for CASGEVY, its lead candidate for treatment of sickle cell disease and beta-thalassemia. This treatment is now available in 25 authorized centers around the world. Cassa ...

Biotech stocks to buy now reflect a more dynamic shift in investor focus of late. Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Global vaccine sales for the crippling virus were upwards of $142 billion from 2020 to 2023. The vaccine rollout was hugely successful across the globe, especially in countries like the U.S., U.K. and Germany. That said, here are three compelling biotech stocks that fit the bill and have the potential to brighten ...

Gene-editing pioneer CRISPR Therapeutics (CRSP 1.22%) stands out in this regard. Despite serious doubt from many in the scientific community, the biotech successfully advanced its gene-edited therapy Casgevy through clinical trials and subsequently won regulatory approvals in several territories such as the U.S., U.K., the European Union, and the Kingdom of Saudi Arabia for both sickle cell disease (SCD) and transfusiondependent beta-thalassemia (TDT). Morningstar analyst Rachel Elfman recently placed a $11 ...

CRISPR Therapeutics (CRSP) In Q1 of 2024, the company reported a net loss of $116.6 million, a significant increase from the prior year's $53 million. This was due to CRSP's strategic investments in R&D and market expansion for Casgevy. Despite this, the firm boasts a robust cash reserve of approximately $2.1 billion, underpinning its capacity for sustained growth and further drug approvals expected in the next two to three years. Vertex Pharmaceuticals (NASDAQ:VRTX) is known for its pioneering cystic fibro ...

Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body. All to treat cancers, blood issues, blindness, cystic fibrosis, and muscular dystrophy. All of which is creating substantial opportunities for some of the leading gene editing stocks. Plus, At the moment, there are about 7,000 diseases caused by genetic disorders. All of which occur when a mutation affects your genes. Or, when you have the wrong amount of genetic material, as ...

Heading into today, shares of the company had gained 2.02% over the past month, lagging the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% in that time. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$5.51 per share and revenue of $89.43 million, indicating changes of -184.02% and -75.91%, respectively, compared to the previous year. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investor ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market pri ...

Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.37 per share, which would represent a year-over-year decline of 39.8%. Our most recent consensus estimate is calling for quarterly revenue of $8.39 million, down 88.02% from the year-ago period. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Z ...